Literature DB >> 34839308

How many is too many? Polyposis syndromes and what to do next.

Nina Gupta1, Christine Drogan, Sonia S Kupfer.   

Abstract

PURPOSE OF REVIEW: The goal of this review is to help providers recognize, diagnose and manage gastrointestinal (GI) polyposis syndromes. RECENT
FINDINGS: Intestinal polyps include a number of histological sub-types such as adenomas, serrated, hamartomas among others. Over a quarter of individuals undergoing screening colonoscopy are expected to have colonic adenomas. Although it is not uncommon for adults to have a few GI polyps in their lifetime, some individuals are found to have multiple polyps of varying histology throughout the GI tract. In these individuals, depending on polyp histology, number, location and size as well as extra-intestinal features and/or family history, a polyposis syndrome should be considered with appropriate testing and management.
SUMMARY: Diagnosis and management of polyposis syndromes has evolved with advent of multigene panel testing and new data on optimal surveillance strategies. Evidence-based recommendations and current practice guidelines for polyposis syndromes are reviewed here. Areas of uncertainty and future research are also highlighted.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2022        PMID: 34839308      PMCID: PMC8648991          DOI: 10.1097/MOG.0000000000000796

Source DB:  PubMed          Journal:  Curr Opin Gastroenterol        ISSN: 0267-1379            Impact factor:   3.287


  91 in total

1.  Adenomatous polyposis families that screen APC mutation-negative by conventional methods are genetically heterogeneous.

Authors:  Elise T Renkonen; Pekka Nieminen; Wael M Abdel-Rahman; Anu-Liisa Moisio; Irma Järvelä; Sirpa Arte; Heikki J Järvinen; Päivi Peltomäki
Journal:  J Clin Oncol       Date:  2005-08-20       Impact factor: 44.544

2.  AXIN2-associated autosomal dominant ectodermal dysplasia and neoplastic syndrome.

Authors:  Monica L Marvin; Serina M Mazzoni; Casey M Herron; Sean Edwards; Stephen B Gruber; Elizabeth M Petty
Journal:  Am J Med Genet A       Date:  2011-03-17       Impact factor: 2.802

3.  Associations of Pathogenic Variants in MLH1, MSH2, and MSH6 With Risk of Colorectal Adenomas and Tumors and With Somatic Mutations in Patients With Lynch Syndrome.

Authors:  Christoph Engel; Aysel Ahadova; Toni T Seppälä; Stefan Aretz; Marloes Bigirwamungu-Bargeman; Hendrik Bläker; Karolin Bucksch; Reinhard Büttner; Wouter T de Vos Tot Nederveen Cappel; Volker Endris; Elke Holinski-Feder; Stefanie Holzapfel; Robert Hüneburg; Maarten A J M Jacobs; Jan J Koornstra; Alexandra M Langers; Anna Lepistö; Monika Morak; Gabriela Möslein; Päivi Peltomäki; Kirsi Pylvänäinen; Nils Rahner; Laura Renkonen-Sinisalo; Karsten Schulmann; Verena Steinke-Lange; Albrecht Stenzinger; Christian P Strassburg; Paul C van de Meeberg; Mariette van Kouwen; Monique van Leerdam; Deepak B Vangala; Juda Vecht; Marie-Louise Verhulst; Magnus von Knebel Doeberitz; Jürgen Weitz; Silke Zachariae; Markus Loeffler; Jukka-Pekka Mecklin; Matthias Kloor; Hans F Vasen
Journal:  Gastroenterology       Date:  2020-01-08       Impact factor: 22.682

4.  A Multi-Institutional Cohort of Therapy-Associated Polyposis in Childhood and Young Adulthood Cancer Survivors.

Authors:  Leah H Biller; Chinedu Ukaegbu; Tara G Dhingra; Carol A Burke; Yana Chertock; Anuradha Chittenden; James M Church; Erika S Koeppe; Brandie H Leach; Elana Levinson; Ramona M Lim; Megan Lutz; Erin Salo-Mullen; Rania Sheikh; Gregory Idos; Fay Kastrinos; Elena Stoffel; Jennifer M Weiss; Michael J Hall; Matthew F Kalady; Zsofia K Stadler; Sapna Syngal; Matthew B Yurgelun
Journal:  Cancer Prev Res (Phila)       Date:  2020-02-12

Review 5.  Contribution to colonic polyposis of recently proposed predisposing genes and assessment of the prevalence of NTHL1- and MSH3-associated polyposes.

Authors:  Mariona Terradas; Pau M Munoz-Torres; Sami Belhadj; Gemma Aiza; Matilde Navarro; Joan Brunet; Gabriel Capellá; Laura Valle
Journal:  Hum Mutat       Date:  2019-07-29       Impact factor: 4.878

6.  Effect of Sulindac and Erlotinib vs Placebo on Duodenal Neoplasia in Familial Adenomatous Polyposis: A Randomized Clinical Trial.

Authors:  N Jewel Samadder; Deborah W Neklason; Kenneth M Boucher; Kathryn R Byrne; Priyanka Kanth; Wade Samowitz; David Jones; Sean V Tavtigian; Michelle W Done; Therese Berry; Kory Jasperson; Lisa Pappas; Laurel Smith; Danielle Sample; Rian Davis; Matthew K Topham; Patrick Lynch; Elena Strait; Wendy McKinnon; Randall W Burt; Scott K Kuwada
Journal:  JAMA       Date:  2016 Mar 22-29       Impact factor: 56.272

7.  Somatic APC mosaicism: an underestimated cause of polyposis coli.

Authors:  F J Hes; M Nielsen; E C Bik; D Konvalinka; J T Wijnen; E Bakker; H F A Vasen; M H Breuning; C M J Tops
Journal:  Gut       Date:  2007-06-29       Impact factor: 23.059

8.  Low frequency of POLD1 and POLE exonuclease domain variants in patients with multiple colorectal polyps.

Authors:  Fadwa A Elsayed; Carli M J Tops; Maartje Nielsen; Dina Ruano; Hans F A Vasen; Hans Morreau; Frederik J Hes; Tom van Wezel
Journal:  Mol Genet Genomic Med       Date:  2019-03-02       Impact factor: 2.183

9.  Contribution of New Adenomatous Polyposis Predisposition Genes in an Unexplained Attenuated Spanish Cohort by Multigene Panel Testing.

Authors:  Víctor Lorca; Daniel Rueda; Lorena Martín-Morales; María Jesús Fernández-Aceñero; Judith Grolleman; Carmen Poves; Patricia Llovet; Sandra Tapial; Vanesa García-Barberán; Julián Sanz; Pedro Pérez-Segura; Richarda M de Voer; Eduardo Díaz-Rubio; Miguel de la Hoya; Trinidad Caldés; Pilar Garre
Journal:  Sci Rep       Date:  2019-07-08       Impact factor: 4.379

Review 10.  The Management of Peutz-Jeghers Syndrome: European Hereditary Tumour Group (EHTG) Guideline.

Authors:  Anja Wagner; Stefan Aretz; Annika Auranen; Marco J Bruno; Giulia M Cavestro; Emma J Crosbie; Anne Goverde; Anne Marie Jelsig; Andrew Latchford; Monique E van Leerdam; Anna Lepisto; Marta Puzzono; Ingrid Winship; Veronica Zuber; Gabriela Möslein
Journal:  J Clin Med       Date:  2021-01-27       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.